{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:51:27Z","timestamp":1793393487121,"version":"4.5.0"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018689","name":"Spanish Clinical Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Sepsis is a frequent complication in immunosuppressed cancer patients and hematopoietic stem cell transplant recipients that is associated with high morbidity and mortality rates. The worldwide emergence of antimicrobial resistance is of special concern in this population because any delay in starting adequate empirical antibiotic therapy can lead to poor outcomes. In this review, we aim to address: (1) the mechanisms involved in the development of sepsis and septic shock in these patients; (2) the risk factors associated with a worse prognosis; (3) the impact of adequate initial empirical antibiotic therapy given the current era of widespread antimicrobial resistance; and (4) the optimal management of sepsis, including adequate and early source control of infection, optimized antibiotic use based on the pharmacokinetic and pharmacodynamics changes in these patients, and the role of the new available antibiotics.<\/jats:p>","DOI":"10.3389\/fmed.2021.636547","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:52:40Z","timestamp":1617151960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":104,"title":["Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance"],"prefix":"10.3389","volume":"8","author":[{"given":"Carlota","family":"Gudiol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaia","family":"Albasanz-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2016.0289","article-title":"Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Shankar-Hari","year":"2016","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1097\/CCM.0b013e31823c8d03","article-title":"A comparison of critical care research funding and the financial burden of critical illness in the United States","volume":"40","author":"Coopersmith","year":"2012","journal-title":"Crit Care Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.CCM.0000194535.82812.BA","article-title":"The effect of age on the development and outcome of adult sepsis","volume":"34","author":"Martin","year":"2006","journal-title":"Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/CCM.0000000000000710","article-title":"The epidemiology of chronic critical illness in the United States*","volume":"43","author":"Kahn","year":"2015","journal-title":"Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1378\/chest.129.6.1432","article-title":"The epidemiology of sepsis in patients with malignancy","volume":"129","author":"Danai","year":"2006","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/cc7713","article-title":"Characteristics and outcomes of cancer patients in European ICUs","volume":"13","author":"Taccone","year":"2009","journal-title":"Crit Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1586\/14787210.2014.920253","article-title":"Antibiotic resistance in cancer patients","volume":"12","author":"Gudiol","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0033.","article-title":"Epidemiology, risk factors, and clinical outcomes of bloodstream infection due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in hematologic malignancy: a retrospective study from central south China","author":"Liang","year":"2020","journal-title":"Microb Drug Resist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/jac\/dkp411","article-title":"Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome","volume":"65","author":"Gudiol","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cmi.2014.11.022","article-title":"Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey","volume":"21","author":"Trecarichi","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2013.07.018","article-title":"Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in patients with cancer","volume":"42","author":"Ha","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00277-012-1424-3","article-title":"P. aeruginosa bloodstream infections among hematological patients: an old or new question?","volume":"91","author":"Cattaneo","year":"2012","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0249419","DOI":"10.1128\/AAC.01521-19","article-title":"Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa","volume":"64","author":"Gudiol","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e13186","DOI":"10.1111\/tid.13186","article-title":"Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies. Results from a multicentric surveillance cohort study","volume":"21","author":"Kern","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the european bone marrow transplantation group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","article-title":"Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies","volume":"73","author":"Satlin","year":"2016","journal-title":"J Infect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijantimicag.2016.01.011","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases","volume":"47","author":"Tofas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-017-2297-9","article-title":"Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias","volume":"17","author":"Micozzi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00277-018-3341-6","article-title":"Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria","volume":"97","author":"Cattaneo","year":"2018","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ajh.24489","article-title":"Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey","volume":"91","author":"Trecarichi","year":"2016","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/cid\/ciz319","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/QCO.0000000000000685","article-title":"Treatment of extended-spectrum \u03b2-lactamases infections: what is the current role of new \u03b2-lactams\/\u03b2-lactamase inhibitors?","volume":"33","author":"Bassetti","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.2016.66.9549","article-title":"Efects of organizational characteristics on outcomes and resource use in patients with cancer admitted to intensive care units","volume":"34","author":"Soares","year":"2016","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1097\/CCM.0b013e31829a6e89","article-title":"Profile of the risk of death after septic shock in the present era: an epidemiologic study","volume":"41","author":"Pavon","year":"2013","journal-title":"Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2016.2691","article-title":"Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis","volume":"315","author":"van Vught","year":"2016","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/CCM.0000000000003896","article-title":"Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations","volume":"47","author":"Hensley","year":"2019","journal-title":"Crit Care Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jcrc.2011.06.014","article-title":"Critically ill patients with cancer and sepsis: clinical course and prognostic factors","volume":"27","author":"Rosolem","year":"2012","journal-title":"J Crit Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CCM.0b013e3181c0349e","article-title":"Characteristics and outocomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study","volume":"38","author":"Soares","year":"2010","journal-title":"Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/CCM.0B013E318165314B","article-title":"Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit","volume":"36","author":"P\u00e8ne","year":"2008","journal-title":"Crit Care Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCM.0b013e31822d74ba","article-title":"Impact of case volume on survival of septic shock in patients with malignancies","volume":"40","author":"Zuber","year":"2012","journal-title":"Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit Care Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1097\/CCM.0000000000004322","article-title":"Sepsis and septic shock in patients with malignancies: a groupe de recherche respiratoire en reanimation oncohematologique study","volume":"48","author":"Lemiale","year":"2020","journal-title":"Crit Care Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium\u2013a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study","volume":"31","author":"Azoulay","year":"2013","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1097\/CCM.0000000000002589","article-title":"Characteristics and outcome of cancer patients admitted to the ICU in England, Wales, and Northern Ireland and National trends between 1997 and 2013","volume":"45","author":"Ostermann","year":"2017","journal-title":"Crit Care Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13613-015-0058-8","article-title":"Timing and causes of death in septic shock","volume":"5","author":"Daviau","year":"2015","journal-title":"Ann Intensive Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1097\/CCM.0000000000002722","article-title":"Time course of septic shock in immunocompromised and nonimmunocompromised patients","volume":"45","author":"Jamme","year":"2017","journal-title":"Crit Care Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s00134-015-4076-7","article-title":"Organizational characteristics, outcomes, and resource use in 78 Brazilian intensive care units: the ORCHESTRA study","volume":"41","author":"Soares","year":"2015","journal-title":"Intensive Care Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1097\/CCM.0000000000000989","article-title":"Effect of early intervention on long-term outcomes of critically ill cancer patients admitted to ICUs","volume":"43","author":"Lee","year":"2015","journal-title":"Crit Care Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jcrc.2020.01.027","article-title":"One-year survival in patients with s\u00f2lid tumours discharged alive from the intensive care unit after unplanned admission: a retrospective study","volume":"57","author":"Borcoman","year":"2020","journal-title":"J Crit Care"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/10428194.2017.1375106","article-title":"Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study","volume":"59","author":"Tavares","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00520-019-04937-4","article-title":"Long-term prognosis of septic shock in cancer patients","volume":"28","author":"Camou","year":"2020","journal-title":"Support Care Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1097\/CCM.0000000000000525","article-title":"Exploring the scope of post-intensive care syndrome therapy and care: engagement of non-critical care providers and survivors in a second stakeholders meeting","volume":"42","author":"Elliott","year":"2014","journal-title":"Crit Care Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"R291","DOI":"10.1186\/cc2893","article-title":"Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care","volume":"8","author":"Williams","year":"2004","journal-title":"Crit Care"},{"key":"B49","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/1471-2407-10-516","article-title":"Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study","volume":"10","author":"Roze","year":"2010","journal-title":"BMC Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJM197105132841904","article-title":"Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia","volume":"284","author":"Schimpff","year":"1971","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/CCM.0000000000000714","article-title":"Milwaukee initiative in critical care outcomes research group of investigators. Severe sepsis in hematopoietic stem cell transplant recipients","volume":"43","author":"Kumar","year":"2015","journal-title":"Crit Care Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/21505594.2016.1141161","article-title":"Bloodstream infections in patients with solid tumors","volume":"7","author":"Gudiol","year":"2016","journal-title":"Virulence"},{"key":"B54","first-page":"329","article-title":"Bloodstream infections in cancer patients","volume":"80","author":"Sierra","year":"2020","journal-title":"Medicina."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e0125019","DOI":"10.1128\/AAC.01250-19","article-title":"Shock and early death in hematologic patients with febrile neutropenia","volume":"63","author":"Guarana","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B56","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/imr.12499","article-title":"The immune system's role in sepsis progression, resolution and long-term outcome","volume":"274","author":"Delano","year":"2016","journal-title":"Immunol Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI82224","article-title":"Sepsis-induced immunre dysfunction: can immune therapies reduce mortality?","volume":"126","author":"Delano","year":"2016","journal-title":"J Clin Invest"},{"key":"B58","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nri2402","article-title":"Harmful molecular mechanisms in sepsis","volume":"8","author":"Rittirsch","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.it.2012.09.004","article-title":"The inflammatory response in sepsis","volume":"34","author":"Bosmann","year":"2013","journal-title":"Trends Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1096\/fj.00-0653fje","article-title":"Protective effects of anti-C5a peptide antibodies in experimental sepsis","volume":"15","author":"Huber-Lang","year":"2001","journal-title":"FASEB J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/SHK.0b013e318257114e","article-title":"Generation of nitric oxide and reactive oxygen species by neutrophils and monocytes from septic patients and association with outcomes","volume":"38","author":"Santos","year":"2012","journal-title":"Shock"},{"key":"B62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(02)09459-X","article-title":"Association between mitochondrial dysfunction and severity and outcome of septic shock","volume":"360","author":"Brealey","year":"2002","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-005-0086-4","article-title":"Failure of neutrophil chemotactic function in breats cancer patients treated with chemotherapy","volume":"57","author":"Mendon\u00e7a","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","article-title":"Lymphocyte recovery is impaied in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab","volume":"93","author":"Garc\u00eda","year":"2014","journal-title":"Ann Hematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/MOH.0b013e328353bc7d","article-title":"Immune reconstitution after hematopoietic stem cell transplantation","volume":"19","author":"Bosch","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s00134-012-2582-4","article-title":"Septic shock and chemotherapy-induced cytopenia: effects on microcirculation","volume":"38","author":"Karvunidis","year":"2012","journal-title":"Intensive Care Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic s\u00edndromes","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s13054-016-1537-5","article-title":"Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study","volume":"20","author":"Contou","year":"2016","journal-title":"Crit Care"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3109\/10428194.2014.887709","article-title":"Respiratory events at the earliest phase of acute myeloid leukemia","volume":"55","author":"Moreau","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1097\/CCM.0000000000002990","article-title":"Urgent chemotherapy in sepsis-like shock related to hematologic malignancies","volume":"46","author":"Cherrualut","year":"2018","journal-title":"Crit Care Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentitation syndrome in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/cid\/ciy530","article-title":"Sepsis and risk of cancer among elderly adults in the United States","volume":"68","author":"Liu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic imjne stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic s\u00edndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2009-09-241083","article-title":"The post sepsis-induced expansion and enhanced function of regulatory T cells create an enviroment to potentiate tumor growth","volume":"115","author":"Cavassani","year":"2010","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-15-0170","article-title":"Post-sepsis State induces tumor-associated macrophage accumulation through CXCR4\/CXCL12 and favors tumor progression in mice","volume":"4","author":"Mota","year":"2016","journal-title":"Cancer Inmunol Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00277-003-0741-y","article-title":"Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection-case report and review of the literature","volume":"83","author":"Maywald","year":"2004","journal-title":"Ann Hematol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/00006123-199903000-00110","article-title":"Long-term remission of malignant brain tumors after intracranial infection: a report of four cases","volume":"44","author":"Bowles","year":"1999","journal-title":"Neurosurgery"},{"key":"B80","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jid.2015.12.032","article-title":"Bacterial sepsis increases survival in metastatic melanoma: Chlamydophila pneumoniae induces macrophage polarization and tumor regression","volume":"136","author":"Buzas","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.4049\/jimmunol.1900076","article-title":"Cutting edge: polymicrobial sepsis has the capacity to reinvigorate tumor-infiltrating CD8 T cells and prolong host survival","volume":"202","author":"Danahy","year":"2019","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1641391","DOI":"10.1080\/2162402X.2019.1641391","article-title":"Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity","volume":"8","author":"Vigneron","year":"2019","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/s41467-019-10354-2","article-title":"A tolllike receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages","volume":"10","author":"Feng","year":"2019","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1513\/AnnalsATS.201501-046OC","article-title":"Sepsis-associated outcomes in critically ill patients with malignancies","volume":"12","author":"Torres","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.3802\/jgo.2020.31.e62","article-title":"Incidence and clinical course of s\u00e8ptic shock in neutropenic patients during chemtherapy for gynecological cancers","volume":"31","author":"Yoo","year":"2020","journal-title":"J Gynecol Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12094-018-1905-5","article-title":"Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era","volume":"21","author":"Mar\u00edn","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e0229828","DOI":"10.1371\/journal.pone.0229828","article-title":"Antibiotic prescribing and outcomes in cancer patients with febrile neutropenia in the emergency department","volume":"15","author":"Peyrony","year":"2020","journal-title":"PLoS ONE"},{"key":"B91","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jinf.2009.02.002","article-title":"Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies","volume":"58","author":"Trecarichi","year":"2009","journal-title":"J Infect"},{"key":"B92","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/jac\/dkq494","article-title":"Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes","volume":"66","author":"Gudiol","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"B93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1473-3099(20)30477-1","article-title":"Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals","volume":"21","author":"Kadri","year":"2020","journal-title":"Lancet infect Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cmi.2015.01.029","article-title":"Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection","volume":"21","author":"Mar\u00edn","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"B95","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"885066619894933","DOI":"10.1177\/0885066619894933","article-title":"Sepsis and septic shock definitions in patients with cancer admitted in iCU","volume":"23","author":"Nathan","year":"2019","journal-title":"J Intensive Care Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/ajco.13422","article-title":"Prognostic performance of qSOFA in oncology patients admitted to the emergency department with suspected infection","volume":"17","author":"Koh","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/ejh.13500","article-title":"Febrile neutropenia in patients with acute myeloid leukemia: outcome in relation to qSOFA score, C-reactive protein, and blood culture findings","volume":"105","author":"Lappalainene","year":"2020","journal-title":"Eur J Haematol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/cc8872","article-title":"Sepsis biomarkers: a review","volume":"14","author":"Pierrakos","year":"2010","journal-title":"Crit Care"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00520-015-2650-8","article-title":"Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diganosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis","volume":"23","author":"Wu","year":"2015","journal-title":"Support Care Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e0225765","DOI":"10.1371\/journal.pone.0225765","article-title":"Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies","volume":"14","author":"Yang","year":"2019","journal-title":"PLoS ONE."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00147","article-title":"Procalcitonin and C-reactive protein as markers of bacteremia in patients with febrile neutropenia who receive chemotherapy for acute leukemia: a prospective study from Nepal","volume":"5","author":"Shilpakar","year":"2019","journal-title":"J Glob Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2020.07.024","article-title":"Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients","volume":"510","author":"Blouin","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1080\/10428190802258956","article-title":"Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia","volume":"49","author":"Prat","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.3109\/10428194.2011.597904","article-title":"Biomarkers for bacteremia andsevere sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis","volume":"52","author":"Juutilainen","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B107","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/apm.12406","article-title":"Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-adrenomedullin (MR-proADM) in bacterial infections","volume":"123","author":"Angeletti","year":"2015","journal-title":"APMIS."},{"key":"B108","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis1029","article-title":"Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies","volume":"56","author":"Al","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1097\/CCM.0000000000000526","article-title":"The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*","volume":"42","author":"Debiane","year":"2014","journal-title":"Crit Care Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e2019047","DOI":"10.4084\/mjhid.2019.047","article-title":"Comparison of presepsin, procalcitonin, interleukin-8 and c-reactive protein in predicting bacteraemia in febrile neutropenic adult patients with haematological malignancies","volume":"11","author":"Kostic","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for emperical antibacterial therapy for febrile neutropenic patients in the era of growing resistance","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"B112","doi-asserted-by":"publisher","first-page":"CD003344","DOI":"10.1002\/14651858.CD003344.pub3","article-title":"Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis","volume":"2014","author":"Paul","year":"2014","journal-title":"Cochrane database Syst Rev."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/cid\/cix186","article-title":"Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: a prospective observational cohort study","volume":"64","author":"Ong","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1128\/AAC.00115-10","article-title":"Influence of empiric therapy with a \u03b2-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms","volume":"54","author":"Mart\u00ednez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1097\/CCM.0b013e3181eb3ccd","article-title":"Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis","volume":"38","author":"Kumar","year":"2010","journal-title":"Crit Care Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s15010-018-1125-5","article-title":"Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients","volume":"46","author":"Hakki","year":"2018","journal-title":"Infection"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e02340","DOI":"10.1128\/AAC.02340-18","article-title":"A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/INF.0000000000001228","article-title":"Use of ceftolozane\/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient","volume":"35","author":"Aitken","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"B119","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jac\/dky393","article-title":"Mechanisms of high-level ceftolozane\/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin","volume":"74","author":"So","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B120","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00277-018-3535-y","article-title":"Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience","volume":"98","author":"Metafuni","year":"2019","journal-title":"Ann Hematol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e02463","DOI":"10.1128\/AAC.02463-18","article-title":"Successful treatment of bacteremia due to NDM-1-producing morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy","volume":"63","author":"Hobson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/CCM.0b013e3181a0054d","article-title":"A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics","volume":"37","author":"Roberts","year":"2009","journal-title":"J Crit Care Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B126","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/QCO.0b013e32835915c2","article-title":"Infusional beta-lactam antibiotics in febrile neutropenia: has the time come?","volume":"25","author":"Abbott","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"B127","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1128\/AAC.49.8.3550-3553.2005","article-title":"Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure","volume":"49","author":"Pea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"B129","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1078155216687151","article-title":"Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia","volume":"24","author":"Wrenn","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dku150","article-title":"Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study","volume":"69","author":"Feh\u00e9r","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/cid\/ciy258","article-title":"Extended versus bolus infusion of broad spectrum \u03b2-lactams for febrile neutropenia: an unblinded randomized trial running title: \u03b2-lactam infusion in febrile neutropenia","volume":"67","author":"Ram","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B132","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/cid\/ciy783","article-title":"Extended infusion of broad-spectrum \u03b2-lactams in high-risk febrile neutropenic patients","volume":"68","author":"Gudiol","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13063-020-04323-0","article-title":"Efficacy of extended infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)","volume":"21","author":"Laporte-Amargos","year":"2020","journal-title":"Trials"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3324\/haematol.2010.031583","article-title":"Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience","volume":"96","author":"Schellongowski","year":"2011","journal-title":"Haematologica"},{"key":"B136","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00432-018-2581-0","article-title":"Clinical characteristics and outcomes of cancer patients requiring intensive care unit admission: a prospective study","volume":"144","author":"Martos-Ben\u00edtez","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.blre.2015.04.002","article-title":"Managing critically ill hematology patients: time to think differently","volume":"29","author":"Azoulay","year":"2015","journal-title":"Blood Rev"},{"key":"B138","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2110-5820-1-5","article-title":"Intensive care of the cancer patient: recent achievements and remaining challenges","volume":"1","author":"Azoulay","year":"2011","journal-title":"Ann Intensive Care"},{"key":"B139","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00134-008-1320-4","article-title":"Continued survival gains in recent years among critically ill myeloma patients","volume":"35","author":"Peigne","year":"2009","journal-title":"Intensive Care Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s001340051087","article-title":"Changing use of intensive care for hematological patients: the example of multiple myeloma","volume":"25","author":"Azoulay","year":"1999","journal-title":"Intensive Care Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00134-014-3615-y","article-title":"Prognosis of neutropenic patients admitted to the intensive care unit","volume":"41","author":"Mokart","year":"2015","journal-title":"Intensive Care Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/PAS.0000000000000517","article-title":"Neutropenic enterocolitis: new insights into a deadly entity","volume":"39","author":"Sachak","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00134-013-3148-9","article-title":"De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study","volume":"40","author":"Mokart","year":"2014","journal-title":"Intensive Care Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00134-005-2836-5","article-title":"Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit","volume":"32","author":"Benoit","year":"2006","journal-title":"Intensive Care Med"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00277-014-2141-x","article-title":"Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit","volume":"93","author":"Wohlfarth","year":"2014","journal-title":"Ann Hematol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1097\/01.CCM.0000181728.13354.0A","article-title":"Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy","volume":"33","author":"Darmon","year":"2005","journal-title":"Crit Care Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jcrc.2019.07.002","article-title":"Rescue stem cell allograft in intensive care unit patients during septic shock with multi-organ failure","volume":"54","author":"Lepr\u00eatre","year":"2019","journal-title":"J Crit Care"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.636547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:52:45Z","timestamp":1617151965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.636547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":147,"alternative-id":["10.3389\/fmed.2021.636547"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.636547","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"article-number":"636547"}}